Last reviewed · How we verify
ethinyl estradiol/etonogestrel vaginal ring
Ethinyl estradiol and etonogestrel work together as a combined hormonal contraceptive that suppresses ovulation and alters cervical mucus to prevent pregnancy.
Ethinyl estradiol and etonogestrel work together as a combined hormonal contraceptive that suppresses ovulation and alters cervical mucus to prevent pregnancy. Used for Contraception in women of reproductive age.
At a glance
| Generic name | ethinyl estradiol/etonogestrel vaginal ring |
|---|---|
| Also known as | Nuvaring |
| Sponsor | University of Pittsburgh |
| Drug class | Combined hormonal contraceptive |
| Target | Estrogen receptor and progesterone receptor |
| Modality | Small molecule |
| Therapeutic area | Contraception / Reproductive Health |
| Phase | FDA-approved |
Mechanism of action
Ethinyl estradiol is a synthetic estrogen and etonogestrel is a synthetic progestin. Together they inhibit the luteinizing hormone (LH) and follicle-stimulating hormone (FSH) surges needed for ovulation. The progestin component also thickens cervical mucus to impede sperm transport and alters the endometrium to prevent implantation. The vaginal ring formulation provides sustained hormone release over a 3-week cycle.
Approved indications
- Contraception in women of reproductive age
Common side effects
- Headache
- Nausea
- Vaginal irritation or discomfort
- Breast tenderness
- Mood changes
- Breakthrough bleeding
Key clinical trials
- Does Vaginal Delivery of Combined Hormonal Contraception Affect the Risk of Metabolic Syndrome in Overweight/Obese Women With PCOS (PHASE4)
- Assessing the Impact of Contraceptives on Bone Health Using 41Ca (PHASE4)
- Comparative Bioavailability Study of Ethinyl Estradiol/Etonogestrel Vaginal Ring (PHASE1)
- A Study to Evaluate the Effectiveness of NuvaRing® to Prevent Pregnancies in Chinese Women (P06450) (PHASE3)
- A Dose-Finding Study to Evaluate Ovarian Function and Vaginal Bleeding in Next Generation Rings (P06109/MK-8175A/MK-8342B-012) (PHASE2)
- Study of the Use of a Contraceptive Vaginal Ring (NuvaRing) in Normal Daily Practice in Indian Women (P07733) (PHASE4)
- Efficacy and Safety of Etonogestrel + 17β-Estradiol Vaginal Ring and Levonorgestrel-Ethinyl Estradiol Combined Oral Contraceptive in Adult Women at Risk for Pregnancy (MK-8342B-062) (PHASE3)
- Inpatient Adolescent Contraception (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: